BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21466595)

  • 21. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
    Hooper MJ; Ebeling PR; Roberts AP; Graham JJ; Nicholson GC; D'Emden M; Ernst TF; Wenderoth D
    Climacteric; 2005 Sep; 8(3):251-62. PubMed ID: 16390757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of calcium, vitamin D and a plant-based omega-3 oil for osteopenia: a pilot RCT.
    Vanlint SJ; Ried K
    Maturitas; 2012 Jan; 71(1):44-8. PubMed ID: 22078660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of bone loss in paraplegics over 2 years with alendronate.
    Zehnder Y; Risi S; Michel D; Knecht H; Perrelet R; Kraenzlin M; Zäch GA; Lippuner K
    J Bone Miner Res; 2004 Jul; 19(7):1067-74. PubMed ID: 15176988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
    Watts NB; Geusens P; Barton IP; Felsenberg D
    J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of low-dose cholecalciferol and calcium treatment on posttransplant bone loss in renal transplant patients: a prospective study.
    Sahin G; Yasar NS; Sirmagul B; Bal C; Yalcin AU
    Ren Fail; 2008; 30(10):992-9. PubMed ID: 19016151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. "Twice-a-month" clodronate 200 mg IM: a new dosing regimen and improved therapy adherence in the treatment of postmenopausal osteoporosis.
    Muratore M; Quarta L; Calcagnile F; Quarta E
    Adv Ther; 2010 May; 27(5):314-20. PubMed ID: 20526703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial.
    Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Koukoulis GN; Efstathiadou Z; Kita M; Avramidis A
    Int J Clin Pract; 2008 Jun; 62(6):919-24. PubMed ID: 18422590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
    Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
    Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
    Devogelaer JP; Sambrook P; Reid DM; Goemaere S; Ish-Shalom S; Collette J; Su G; Bucci-Rechtweg C; Papanastasiou P; Reginster JY
    Rheumatology (Oxford); 2013 Jun; 52(6):1058-69. PubMed ID: 23365149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence.
    Eastell R; Vrijens B; Cahall DL; Ringe JD; Garnero P; Watts NB
    J Bone Miner Res; 2011 Jul; 26(7):1662-9. PubMed ID: 21312265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
    Bradbury LA; Barlow S; Geoghegan F; Hannon RA; Stuckey SL; Wass JA; Russell RG; Brown MA; Duncan EL
    Osteoporos Int; 2012 Jan; 23(1):285-94. PubMed ID: 21739105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
    van Bodegraven AA; Bravenboer N; Witte BI; Dijkstra G; van der Woude CJ; Stokkers PC; Russel MG; Oldenburg B; Pierik M; Roos JC; van Hogezand RA; Dik VK; Oostlander AE; Netelenbos JC; van de Langerijt L; Hommes DW; Lips P;
    Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LRP5 Polymorphisms and response to risedronate treatment in osteoporotic men.
    Kruk M; Ralston SH; Albagha OM
    Calcif Tissue Int; 2009 Mar; 84(3):171-9. PubMed ID: 19148563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
    Ringe JD; Farahmand P; Faber H; Dorst A
    Rheumatol Int; 2009 Jan; 29(3):311-5. PubMed ID: 18762944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
    Wallach S; Cohen S; Reid DM; Hughes RA; Hosking DJ; Laan RF; Doherty SM; Maricic M; Rosen C; Brown J; Barton I; Chines AA
    Calcif Tissue Int; 2000 Oct; 67(4):277-85. PubMed ID: 11000340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate.
    Khedr NF; El-Ashmawy NE; El-Bahrawy HA; Haggag AA; El-Abd EE
    Fundam Clin Pharmacol; 2013 Oct; 27(5):526-34. PubMed ID: 22762129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial.
    Waltman NL; Twiss JJ; Ott CD; Gross GJ; Lindsey AM; Moore TE; Berg K; Kupzyk K
    Osteoporos Int; 2010 Aug; 21(8):1361-9. PubMed ID: 19802506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone mineral density in the long term after liver transplantation.
    Hamburg SM; Piers DA; van den Berg AP; Slooff MJ; Haagsma EB
    Osteoporos Int; 2000; 11(7):600-6. PubMed ID: 11069194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.